CompletedPhase 2NCT00356031
Bevacizumab and Radiation Therapy for Sarcomas
Studying Fibrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Yen-Lin Chen, MDMassachusetts General Hospital
- Intervention
- Bevacizumab(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2010
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Collaborators
National Institutes of Health (NIH) · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00356031 on ClinicalTrials.govOther trials for Fibrosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05566795DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Day One Biopharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03834961Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaChildren's Oncology Group